Martin Shkreli Quits As Turing Pharmaceuticals CEO, But What Will Happen To Him?

The most hated person on the Internet’s week just got a lot worse. Following his arrest for securities fraud, Martin Shkreli stepped down as Turning Pharmaceuticals CEO, CNNMoney reported on Thursday. Though he boasted a hip-hop-fueled, lavish lifestyle — to the resentment of his many detractors — it’s unclear what the future will hold for the 32-year-old.

“Schadenfreude” is a word are many are using to describe the situation. He’s in legal hot water for allegedly running a “Ponzi-like” scheme while at Retrophin as CEO, but Shkreli became super infamous for raising an AIDS drug from $13.50 to $750 per pill — a whopping 5,000 percent increase — when he was running Turning Pharma. What makes this decision even more questionable to some is that the medication, called Daraprim, not only treats AIDS patients, but infants and other vulnerable people with weakened immune systems, according to TIME.

While Shkreli was released from jail Thursday afternoon, he faces securities fraud, securities fraud conspiracy, and wire fraud conspiracy charges for allegedly shifting millions in Retrophin stock and cash by carrying out fraudulent consulting deals. And these charges are nothing to sneeze at, as VICE reports he could be looking at as many as 20 years in prison if convicted.

But what can we expect from in him the meantime? Well, if you’re unaware, Shkreli was a biotech executive by day and an aspiring hip-hop mogul by night, and there’s no indication that he’s giving up on the second endeavor. On Dec. 9, Shkreli paid $2 million a Wu-Tang clan album, the only one in circulation.